Quarterly report · Q2
4882.TEDINET S100PJIS
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥48m | 2022-04-01 → 2022-09-30 | Standalone | Net sales |
| Revenue | ¥72m | 2021-04-01 → 2022-03-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥29m | 2021-04-01 → 2021-09-30 | Standalone | Net sales |
| Operating income | −¥307m | 2022-04-01 → 2022-09-30 | Standalone | Operating income |
| Operating income | −¥246m | 2021-04-01 → 2021-09-30 | Standalone | Operating income |
| Ordinary income | −¥289m | 2022-04-01 → 2022-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥482m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥264m | 2021-04-01 → 2021-09-30 | Standalone | Ordinary income |
| Profit before tax | −¥362m | 2022-04-01 → 2022-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥273m | 2021-04-01 → 2021-09-30 | Standalone | Income before income taxes |
| Net income | −¥363m | 2022-04-01 → 2022-09-30 | Standalone | Profit loss |
| Net income | −¥599m | 2021-04-01 → 2022-03-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥274m | 2021-04-01 → 2021-09-30 | Standalone | Profit loss |
| Total assets | ¥2.9bn | at 2022-09-30 | Standalone | Assets |
| Total assets | ¥3.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥3.6bn | at 2021-09-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥90m | at 2022-09-30 | Standalone | Liabilities |
| Total liabilities | ¥148m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.8bn | at 2022-09-30 | Standalone | Net assets |
| Net assets / equity | ¥3.2bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.5bn | at 2021-09-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.8bn | at 2022-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2022-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥3.2bn | at 2022-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2021-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2021-03-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥256m | 2022-04-01 → 2022-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥477m | 2021-04-01 → 2022-03-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥205m | 2021-04-01 → 2021-09-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥156m | 2022-04-01 → 2022-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥34m | 2021-04-01 → 2022-03-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6m | 2021-04-01 → 2021-09-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | −¥20,000 | 2022-04-01 → 2022-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.6bn | 2021-04-01 → 2021-09-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-30.87 | 2022-04-01 → 2022-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.84 | 2022-07-01 → 2022-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-54.47 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-26.77 | 2021-04-01 → 2021-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.36 | 2021-07-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 96.5% | at 2022-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 97.9% | at 2021-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 11,759,400 | at 2022-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,759,400 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,759,400 | at 2021-09-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 363
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes segment information etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment | Prior1YTDDuration_NonConsolidatedMember | Original text (Japanese)当社の事業セグメントは、医薬品事業のみの単一セグメントであるため、セグメント情報の記載を省略しております。 | |
| Description of fact that companys business comprises single segment | CurrentYTDDuration_NonConsolidatedMember | Original text (Japanese)当社の事業セグメントは、医薬品事業のみの単一セグメントであるため、セグメント情報の記載を省略しております。 | |
| Notes revenue recognition quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |